Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on Hard-to-Treat cancers

NCT ID NCT06658951

Recruiting now Disease control Sponsor: UTC Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Mar 21, 2026 · Last updated May 01, 2026 · Updated 10 times

Summary

This study is testing an experimental treatment called Anti-HER2 CAR-T cells for people with advanced solid tumors that have not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to target the HER2 protein on cancer cells, and infusing them back. The main goals are to find a safe dose and to see if the treatment can shrink tumors. About 30 adults aged 18 to 70 with various HER2-positive cancers, such as stomach, breast, or lung cancer, can join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE ADVANCED MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HER2-POSITIVE ADVANCED MALIGNANT SOLID TUMORS